DURECT is committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and lifesaving therapies based on its endogenous epigenetic regulator program. DURECT is focusing its efforts on therapeutic areas with significant unmet need, including diseases with no approved treatments like alcohol-associated hepatitis (AH) and non-alcoholic steatohepatitis (NASH)